SEC Company Response from INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726) (INO) — Mar 27, 2020
INOVIO PHARMACEUTICALS, INC. (INO) (CIK 0001055726)
Date: March 27, 2020 · CIK: 0001055726 · Accession: 0001193125-20-088806
AI Filing Summary & Sentiment
File numbers found in text: 333-237172
Letter
March 27, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey Gabor
RE: Inovio Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 13, 2020
File No. 333-237172
Acceleration Request
Requested Date:
March 31, 2020
Requested Time:
4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on March 31, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Darah Protas of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053 or Darah Protas of Cooley LLP at (202) 962 8332.
Very truly yours,
Inovio Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP March 27, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey Gabor RE: Inovio Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 13, 2020 File No. 333-237172 Acceleration Request Requested Date: March 31, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on March 31, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance. The Registrant hereby authorizes each of Brian Leaf and Darah Protas of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053 or Darah Protas of Cooley LLP at (202) 962 8332. Very truly yours, Inovio Pharmaceuticals, Inc. /s/ Peter Kies Peter Kies Chief Financial Officer cc: Brian Leaf, Cooley LLP Darah Protas, Cooley LLP 6769 Mesa Ridge Road San Diego, CA 92121 Phone: (858) 597-6006 Fax: (858) 404-1392